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Abstract
The emergence of metastatic disease in cancer patients many years or decades after initial 
successful treatment of primary tumors is well documented but poorly understood at the molecular 
level. Recent studies have begun exploring the cell-intrinsic programs causing disseminated tumor 
cells to enter latency and the cellular signals in the surrounding non-permissive tissue 
microenvironment that maintain the latent state. However, relatively little is known about the 
mechanisms that enable disseminated tumor cells to escape cancer dormancy or tumor latency. We 
describe here an in vivo model of solitary metastatic latency in the lung parenchyma. The 
induction of a localized inflammation in the lungs, initiated by lipopolysaccharide (LPS) 
treatment, triggers the awakening of these cells, which develop into macroscopic metastases. The 
escape from latency is dependent on the expression of Zeb1, a key regulator of the epithelial-to-
mesenchymal transition (EMT). Furthermore, activation of the EMT program on its own, as 
orchestrated by Zeb1, is sufficient to incite metastatic outgrowth by causing carcinoma cells to 
enter stably into a metastasis-initiating cellstate.
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INTRODUCTION
Metastasis-related mortality for breast cancer patients often occurs many years after 
treatment of their primary tumors. The cause(s) of latency of disseminated tumor cells 
(DTCs) and the mechanism(s) leading to eruption of metastatic disease remain poorly 
understood (1, 2). At present it is unknown whether each DTC has the potential to act as a 
founder cell of a metastasis, or whether this function is reserved for specialized DTCs 
deemed “metastasis-initiating cells” (MICs). Recent studies of cancer dormancy have 
focused on the cell-intrinsic traits that maintain DTCs in the dormant state (3–5). Although 
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inflammation is widely recognized as a hallmark of cancer and has been shown to 
predispose certain tissues to form primary tumors, far less is known of the role of 
inflammation in metastatic colonization, i.e., in enabling the outgrowth of already-
extravasated cells in distant tissues.
While certain studies have suggested that a pre-inflamed microenvironment can enhance the 
ability of DTCs to extravasate and subsequently colonize a metastatic site (6–9), it has not 
been determined whether an inflamed microenvironment in the vicinity of already-
extravasated latent DTCs can enable their escape from growth arrest. We therefore sought to 
determine whether inflammation, provoked through the administration of lipopolysaccharide 
(LPS) in mice, could trigger the activation of the previously silent epithelial-mesenchymal 
transition (EMT) program in latent DTCs. We postulated that the activation of the EMT 
program, which can be induced by a diverse array of signalsincluding those associated with 
inflammation, could cause latent DTCs to generate MICs and grow into overt metastases.
MATERIALS AND METHODS
Cell Culture
Mouse mammary carcinoma cell lines (D2A1, 67NR and 168 FARN) and TS/A were gifts 
from F. R. Miller and P.L. Lollini, respectively. Cells were maintained as previously 
described (10) and were not authenticated since first acquisition. For activating tetracycline-
inducible gene expression, cells were treated with 1 µg/ml doxycycline hyclate (Sigma 
Aldrich).
Plasmids and lenti-viral infections
Mouse Snail, Twist1, Zeb1 cDNAs obtained from Open Biosystems were subcloned into 
FUW-LPT2 lentiviral vector (modified from FUW-tetO) with puromycin resistance gene. 
pMMP-LucNeo, carrying coding sequences for luciferase and neomycin phosphotransferase, 
were obtained from Dr. Rosalind Segal.
pLKO-puro shZeb1 vectors (shZeb1_A and shZeb1_B) were used as previously described 
(10). Cells were seeded at 5.0 × 105 cells per 10 cm dish and transduced 24 hours later with 
virus in the presence of 5 µg/ml polybrene (EMD Millipore) and selected with 4 µg/
mlpuromycin.
Cell proliferation assay
Cells were seeded at 1.0 × 106 into 10 cm dishes and counted using Vi-CELL Cell Viability 
Analyzer (Beckman Coulter). 1.0 × 103 cells were seeded onto 96-well plates in triplicate; 
viability was measured using CellTiter-Glo (Promega).
Matrigel-on-top
The Matrigel on-top (MoT) culture was performed as described elsewhere (10).
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Quantitative RT-PCR
Total RNA was isolated using the RNeasy Plus Mini kit (Qiagen). Reverse transcription was 
performed with High Capacity cDNA Reverse Transcription Kit (Life Technologies). mRNA 
levels were measured with gene-specific primers using SYBR Green I master mix (Roche) 
on a Roche LightCycler 480 system (Roche). Relative expression levels were normalized to 
β-actin. The PCR primers for Snail, Twist, Zeb1, and β -actin have been described elsewhere 
(10).
Immunoblotting
Western blots were performed as described previously (10) using the following antibodies: 
Snail (Cell Signaling Technology), Twist (Abcam), Zeb1 (Cell Signaling Technology), E-
cadherin (Cell Signaling Technology), GAPDH (Cell Signaling Technology), and actin (Cell 
Signaling Technology).
Animals
Animal studies were conducted following the MIT Committee on Animal Care protocol 
(1014-109-17). 1.0 × 105 tumor cells, unless otherwise indicated, suspended in Matrigel 1:1 
were implanted into the mammary fat pad of BALB/c mice. Tumor incidence and weight 
was measured six to eight weeks post-injection. 1.0 × 105 cells, resuspended in 100 µL of 
PBS, were injected into the lateral tail vein; alternatively 8.0 × 104 cells were injected into 
the left ventricle. Doxycycline-treated water contained 2 mg/ml doxycycline and 10 mg/ml 
sucrose.
Acute Lung Injury—Escherichia coli LPS type 055:B5 (Sigma Aldrich) was delivered by 
intraperitoneally (i.p.) injection at 2mg/kg. Mice were bled retro-orbitally to obtain 
peripheral white blood cell counts. Anti-Ly6G antibody clone 1A8 (200 µg per mouse; 
Bioxcell) was injected i.p. one day prior LPS treatment and twenty-four hours after LPS 
treatment to deplete neutrophils. Anti-CCL2 antibody (200 µg per mouse, Bioxcell) was 
injected i.p. six hours after LPS treatment and again twenty-four hours after LPS treatment 
to deplete circulating monocytes and macrophages. Matching isotype Hamster IgG 
(Bioxcell) served as a control antibody.
Quantification of lung metastases
Whole lung images were taken using a fluorescence dissection microscope (Leica MZ12). 
Colonies visible at 0.8x magnification of objective lens under fluorescence microscopy were 
counted as macro-metastases.
Histology
Lungs were fixed in 4% paraformaldehyde, paraffin-embedded and stained with 
haemotoxylin and eosin. Sections were imaged at 20x with the Aperio slide scanner (Leica 
Biosystems).
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Bioluminescent imaging
Mice were anesthetized with 2.5% isoflurane and injected i.p with 165mg/kg of body weight 
D-luficerin (Caliper Life Sciences) and imaged in an Xenogen IVIS ten minutes after D-
luficerin injection; data were analyzed using Living Image Software version 4.3.1 (Caliper 
Life Sciences).
Flow cytometry
Lungs were minced and incubated in DME + DNAse + collagenase A (Roche) rotating at 
37°C for two hours. Dissociated lungs were then washed twice with PBS, and filtered 
through a 70 µm and 40 µm cell strainer. Cells were stained with CD45 FITC (eBioscience), 
CD11b PerCP-Cyanine 5.5 (eBioscience); F480 PE-Cyanine7 (Affymetrix); CCR2 APC-
Cy7 (BioLegend); Ly6C e450 (Affymetrix); CD45 PE-Cyanine7 (Affymetrix); CD11b 
PerCP-Cyanine5.5 (eBioscience); Ly6C e450 (Affymetrix); Ly6G FITC (BioLegend); CD29 
(Affymetrix) and CD24 (Affymetrix). After incubating on ice for 45 minutes, cells were 
washed twice in PBS with 0.1% BSA, acquired on a Fortessa (BD Biosciences) and 
analyzed using FACSDiva (BD Biosciences).
RESULTS
To generate a model of metastatic dormancy, highly metastatic murine D2A1 mammary 
carcinoma cells (11) pre-labeled with the CSFE vital dye were injected via the tail vein into 
mice, leading to many being trapped in the lungs. Five days later, label-retaining cells, which 
had therefore failed to proliferate within the lungs, were enriched by FACS, expanded in 
vitro, and re-injected into mice (Figure 1a). After 10 successive cycles of such in vivo 
selection, latent cells (denoted D2A1-d) retained the ability to form primary tumors upon 
orthotopic injection of 105 cells into the mammary fat pad, yet failed to proliferate within 
the lung parenchyma four weeks after tail vein injection (Supplementary Tables 1&2). 
However, a significant reduction in primary tumor growth was seen when only 104 D2A1-d 
cells were implanted, suggesting a growth deficiency in vivo when compared with parental 
D2A1 cells (Supplementary Fig. 1a&b). While the D2A1-d cells fail to proliferate within the 
lung parenchyma after four weeks, D2A1-d cells could indeed be recovered from dissociated 
lung tissue following introduction into 2D culture ex vivo, indicating that latent D2A1-d 
cells were still present in a viable form long after tail vein injection.
Previous work demonstrated that induced expression of EMT-inducing transcription factors 
(EMT-TFs) in carcinoma cells enables them to extend filopodium-like-protrusions (FLPs), 
ensuring proliferation within the lung parenchyma following extravasation (10). This 
suggested that defective FLP formation might provide a mechanistic explanation of the 
observed post-extravasation tumor latency of D2A1-d cells. However, we found no 
difference in the ability of the D2A1-d and parental D2A1 cells to extend FLPs 
(Supplementary Fig. 1c), despite the reduced or absent expression of the EMT-TFs Snail, 
Twist and Zeb1 (12) (Figure 1b). Nonetheless, we hypothesized that the EMT program 
might still play a role in triggering the awakening of latent DTCs via an FLP-independent 
mechanism.
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To determine whether induction of an EMT program in latent DTCs would be sufficient to 
enable their escape from tumor latency, we used a doxycycline-inducible vector to express 
either Snail, Twist or Zeb1 in D2A1-d cells (Supplementary Fig. 2a). No proliferative 
advantage was conferred on cells carrying the inducible EMT-TFs in vitro (Supplementary 
Fig. 2b).
We injected untreated D2A1-d cells harboring doxycycline-inducible vectors into the tail 
vein of mice, waited seven days to achieve a post-extravasation latent state, and then treated 
mice with doxycycline to determine whether the EMT program could reactivate metastatic 
growth in the lungs. In more detail, we used two alternative treatment schedules for inducing 
expression of the EMT-TFs. In initial experiments we exposed mice to doxycycline 
continuously for two weeks; in subsequent experiments, we exposed mice to three periodic 
three day-long feedings of doxycycline.
As we found, the alternating interval treatment schedule was more productive for the 
induction of lung metastases in the case of D2A1-d + Zeb1 cells. Thus, continuous 
doxycycline treatment yielded on average eight metastases per lung (Supplementary Fig. 
2d), while interval treatment generated sixteen metastases (Figure 1c&d). In the case of 
D2A1-d + Snail cells, both treatment protocols yielded the same number of metastases per 
lung, and no metastases were observed in the case of D2A1-d + Twist cells.
To determine whether the EMT program could awaken DTCs that experienced a longer 
period of latency, mice injected with D2A1-d + Snail cells were treated with doxycycline 
three weeks after tail vein injection (Supplementary Fig. 2e). Five weeks post-injection, 
mice carrying D2A1-d + Snail cells and treated with doxycycline developed on average 
twenty-nine metastases per lung, while mice that remained untreated developed on average 
fifteen metastases per lung. Although the latent D2A1-d cells retained a measure of 
metastasis-initiating ability, we deemed the observed two-fold increase in metastasis 
formation (taken together with observations presented elsewhere in this report) to be 
significant and indicative of an ability of Snail to awaken otherwise-latent D2A1-d cells.
To determine whether the EMT program had re-programmed D2A1-d cells to a metastasis-
initiating state in a cell-heritable manner, we retrieved D2A1-d cells from EMT-induced 
metastases and re-injected them via the tail vein into naïve hosts. Mice injected with these 
retrieved cells developed over two hundred lung metastases upon secondary passaging 
(Figure 2a). Hence, EMT-TF expression in vivo promoted the acquisition of heritable MIC-
traits in previously latent DTCs.
While the EMT program has been shown to generate cancer stem cell-like cells as gauged 
by an enhanced primary tumor-forming ability, it has been unclear whether the EMT 
program is also associated with the formation of MICs. We used murine stem cell-surface 
markers (10, 13) to conduct in vitro analyses on D2A1-d and parental cells. This revealed 
distinct CD24/CD29 profiles in the various cell populations (Figure 2b). Thus, parental 
D2A1 cells displayed a CD29+CD24− marker profile (indicative of a more stem-like state), 
while D2A1-d cells exhibited a distinct CD29+CD24+ profile. However, upon expression of 
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Zeb1 in vitro, D2A1-d + Zeb1 cells markedly shifted toward a CD29+CD24− profile, which 
was also observed in the Zeb1-induced metastases (Figure 2b).
When we sorted the CD24+ and CD24− cells from in vitro Zeb1-induced D2A1-d cells and 
injected each population into the tail vein of mice, mice injected with the Zeb1-induced 
CD29+CD24− cells formed an average of thirty-six metastases per mouse, whereas the 
CD29+CD24+ cells developed on average two metastases per mouse (Figure 2c). While both 
the CD29+CD24− and CD29+CD24+ cell populations were able to form orthotopic tumors, 
there was a significant difference in tumor-initiating frequencies and tumor weights between 
both cell populations (Figure 2d; Supplementary Table 3) (14). Since this difference was not 
as significant as the large difference observed in their respective abilities to form metastatic 
tumors in the lungs, the CD29+CD24− marker profile could serve to enrich MICs in this cell 
line, enabling the isolation of a distinct subpopulation of tumor-initiating cells that could 
tumor-initiate at the sites of formation of both primary tumors and metastases.
The EMT program can be activated by heterotypic signals under various physiological and 
pathological states (12). While inflammation has been shown to contribute to primary tumor 
progression, the role of inflammation in metastatic colonization is poorly understood (15, 
16). Recent studies have suggested that a pre-inflamed microenvironment in the lungs can 
enhance the ability of DTCs to subsequently colonize a metastatic site (7–9). We, in 
contrast, wished to explore an alternative scenario in which carcinoma cells arrive in an 
initially normal lung microenvironment and only thereafter experience pro-inflammatory 
signals. Thus, we hypothesized that an inflamed tissue microenvironment might release 
EMT-inducing signals, which in turn might spawn the activation of the EMT program in 
latent DTCs, leading to active proliferation and metastatic colonies.
To test this notion, we first injected D2A1-d cells via the tail vein, and thereafter treated 
mice with lipopolysaccharide (LPS), an agent used to provoke pulmonary inflammation (17) 
(Figure 3a&b; Supplementary Fig. 3a). Within four weeks, the mice that had been exposed 
to LPS carried on average seven lung metastases, while the control mice exhibited at most 
one metastasis.
To determine whether this result was idiosyncratic to the D2A1-d cells, we sought to extend 
this result using other weakly metastatic murine carcinoma cell lines. Mice injected with 
67NR cells and treated one week later with LPS formed on average ten metastases per 
mouse, while LPS-untreated mice injected with 67NR cells developed on average four 
metastases (Supplementary Fig. 3b&c).
D2A1-d cells retrieved from the LPS-induced lung metastases expressed elevated levels of 
the Twist and Zeb1 EMT-TFs, consistent with a causal association of the EMT program with 
induced metastatic outgrowth, as the D2A1-d cells do not express these EMT-TFs under 
routine conditions (Figure 3c). To test whether LPS-induced metastatic outgrowth was 
dependent upon the activation of an EMT program within the latent tumor cells, we first 
injected mice with D2A1-d cells carrying an shZeb1 vector; one week later, we treated these 
mice with LPS. Cells experiencing 90% knockdown of Zeb1 expression (shZeb1_B) yielded 
a 26 % incidence of lung tumors, whereas cells experiencing only a 50–80% knockdown 
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(shZeb1_A) yielded a tumor incidence of 40%. These incidence rates contrasted with those 
of cells bearing the control shRNA, in which 75% of mouse hosts developed metastases 
(Figure 3d; Supplementary Table 4).
Of additional interest was the nature of the host cells that mediated the activation of the 
EMT program in the carcinoma cells. We excluded the contribution of the adaptive immune 
system by performing experiments in NOD-SCID mice. Thus, treating NOD-SCID mice 
injected with D2A1-d cells with LPS provoked metastatic outgrowth, yielding an average of 
ten metastases per lungs, while the LPS-untreated mice developed on average three 
metastases per lungs (Supplementary Fig. 3d). These observations argued against the 
involvement of the adaptive immune system in the observed eruption of LPS-induced 
metastases.
LPS is known to activate neutrophils, macrophages and endothelial cells via toll-like 
receptor 4 signaling. To determine whether neutrophils, which are recruited in large numbers 
to the lungs following LPS treatment, contribute to metastatic outgrowth, we treated mice 
with anti-Ly6G antibody to eliminate these immunocytes. Only one mouse injected with 
D2A1-d cells + anti-Ly6G antibody and treated thereafter with LPS developed a metastasis, 
while the mice injected with D2A1-d cells + control IgG antibody and treated with LPS 
developed on average four lung metastases per mouse (Figure 4a&b). Although there was a 
~ 50%reduction in the number of neutrophils following control anti-IgG treatment as 
compared to the baseline level of neutrophils in the lungs (Figure 4a), this was not sufficient 
to abrogate lung metastasis formation, thereby suggesting that there may exist a threshold of 
the number of neutrophils required to facilitate metastatic outgrowth. However, mice treated 
with neutralizing antibody against macrophages and treated thereafter with LPS developed 
on average three lung metastases per mouse as compared to the mice treated with LPS and 
control anti-IgG that developed on average four lung metastases per mouse, suggesting that 
macrophages are not essential for LPS-induced metastatic outgrowth (Figure 4b).
To determine whether these results were specific to the lungs, we injected D2A1-d cells into 
mice via intra-cardiac injection and treated these mice one week later with LPS via i.p. 
injection. Both control mice and LPS-treated mice developed adrenal gland metastases, 
while bone metastases were only apparent in LPS-treated mice (Figure 4c).
DISCUSSION
While a pre-inflamed tissue microenvironment has been shown to foster subsequent 
metastatic outgrowth (7–9), to our knowledge, this is the first example of a study exploring 
the effects of inflammation on previously seeded, latent DTCs. Although we were unable to 
determine the precise molecular mechanism leading to the awakening of latent DTCs by 
neutrophils, we would suggest that the activation of the EMT program within the carcinoma 
cells may depend in part on direct cell-signaling between the latent DTCs and neutrophils, 
achieved either by the release of EMT-inducing cytokines, through the release of neutrophil-
derived proteases (8), or both. Moreover, monocytes and macrophages recruited by 
neutrophils may well complement and augment the activating effects of the latter cells. 
Attesting to the possible generality of the identified mechanism, LPS-induced inflammation 
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enabled not only colonization of the lungs, but also of the bone.While our study focused on a 
single inflammatory agent, it is highly plausible that other pro-inflammatory stimuli could 
similarly ignite the escape of metastatic tumor latency. Moreover, we would suggest that the 
present work represents only the first of a number of diverse experimental models of DTC 
awakening that will be developed in the future, some of which may depend on quite different 
molecular mechanisms and signaling pathways to trigger the eruption of previously 
unapparent metastatic deposits.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Zeb1 expression is sufficient to awaken latent DTCs
(a) Schematic of in vivo strategy (b) Western blot for D2A1-d and parental D2A1 cell lines; 
(c) Schematic of in vivo strategy. Quantification of lung metastases using fluorescent 
dissection microscope at 0.8x magnification; Data are represented as mean ± SEM; n=10; *, 
P< 0.02 by Student’s t test (d) Representative fluorescent images of whole lungs and H&E 
staining of histological sections.
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Figure 2. Zeb1 expression generates “MICs”
(a) Schematic of in vivo strategy. Fluorescent images and representative H&E staining of 
whole lungs; n=6; (b) Flow cytometry analysis of CD29 and CD24-cell surface expression 
of D2A1-d, parental D2A1 and D2A1-d + Zeb1 after five days of doxycycline treatment, 
and tumor cells isolated from Zeb1-induced lung metastases and D2A1 lung metastases; (c) 
Schematic of in vivo strategy. Quantification of lung metastases visible at 0.8x 
magnification;Data are represented as mean ± SEM; n=10; **, P< 0.07; ***, P< 0.001 by 
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Student’s t test. (d) Orthotopic tumor weights of mice as described in Panel c at dilution of 
104 and 103 cells respectively.
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Figure 3. LPS-induced inflammation awakens latent DTCs
(a) In vitro CellTiter-Glo proliferation assay of D2A1-d in the presence or absence of 0.5, 2 
and 5 µg/mL of LPS; n=3; (b) Schematic depiction of in vivo strategy. Representative 
luminescent images of mice previously injected with D2A1-d cells that received LPS 
intraperitoneally; (c) Pooled tumor cells isolated from lung metastases of three individual 
mice following LPS treatment were analyzed for the expression of E-cadherin, Twist and 
Zeb1 by Western blot. Mice are labeled “1”"2” and “3”; (d) Quantification of lung 
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metastases at 0.8x magnification. Data show mean ± SEM; n=10; **, P< 0.005 by Student’s 
t test.
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Figure 4. Neutrophil depletion inhibits reactivation of latent DTCs
(a) Schematic of neutrophil depletion in the lungs following a single injection of anti-Ly6G 
antibody after 48 hours. Percentage of Ly6G+ CD11b+ cells in total CD45+ cells in lungs 48 
hours after matched-control IgG antibody or anti-Ly6G antibody administration; (b) 
Schematic of neutrophil or macrophages depletion strategy following LPS treatment in mice. 
Quantification of lung metastases at 0.8x magnification;n=4–8; ***, P< 0.0003 by Student’s 
t test. (c) Representative images of whole-body tumor distribution of untreated or LPS-
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treated mouse following intra-cardiac injection of D2A1-d cells; 60% of LPS-treated mice 
developed bone metastases; n=12.
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